| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/28/2001 | WO2000078765A3 CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS |
| 06/28/2001 | WO2000077010A3 Substituted heterocycle fused gamma-carbolines |
| 06/28/2001 | WO2000075144A3 Peroxynitrite decomposition catalysts and methods of use thereof |
| 06/28/2001 | WO2000074710A3 Methods for treating diabetes |
| 06/28/2001 | WO2000073344A3 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 06/28/2001 | WO2000071741A3 Dna encoding a human subunit of the 5-ht3 serotonin receptor |
| 06/28/2001 | WO2000070049A3 Extracellular signaling molecules |
| 06/28/2001 | WO2000070047A3 Full-length molecules expressed in human tissues |
| 06/28/2001 | WO2000068181A3 Process for preparing (1r,2s,4r) -(-)-2-[(2'- {n,n-dimethylamino} -ethoxy)] -2-[phenyl] -1,7,7-tri- [methyl] -bicyclo [2.2.1] heptane and pharmaceutically acceptable acid addition salts thereof |
| 06/28/2001 | WO2000067697A3 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
| 06/28/2001 | WO2000066104A3 Ace-2 inhibiting compounds and methods of use thereof |
| 06/28/2001 | WO2000061180A3 Products and methods for treating ptp lar related diseases |
| 06/28/2001 | WO2000057865A3 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation |
| 06/28/2001 | WO2000055321A3 Vertebrate protein slit, dna sequence encoding it and uses thereof |
| 06/28/2001 | US20010005719 Compositions and methods for treatment of mitochondrial diseases |
| 06/28/2001 | DE19962936A1 New beta-aminoacid amide derivatives, are integrin antagonists useful for treating inflammatory, autoimmune or immunological disorders e.g. asthma, diabetes or rheumatoid arthritis |
| 06/28/2001 | DE19961897A1 Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen Using a film coating as taste coating of pharmaceutical dosage forms |
| 06/28/2001 | DE19960204A1 Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament Norlbornylamino substituted derivatives, processes for their preparation, their use as a medicament or diagnostic, and they drug-containing |
| 06/28/2001 | DE19959913A1 Acetylsalicylsäure enthaltendes transdermales System zur Behandlung von Migräne Aspirin-containing transdermal system for the treatment of migraine |
| 06/28/2001 | DE19959049A1 Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen Combination of compounds, which inhibit the biological effects of TNF-alpha and CD95L |
| 06/28/2001 | DE19957065A1 Screening-Verfahren für Arzneistoffe A screening method for drugs |
| 06/28/2001 | CA2399584A1 Non peptide tachykinin receptor antagonists |
| 06/28/2001 | CA2395578A1 Replication incompetent herpes virus vectors |
| 06/28/2001 | CA2395576A1 Replication incompetent herpes viruses for use in gene therapy |
| 06/28/2001 | CA2395520A1 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| 06/28/2001 | CA2395471A1 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives |
| 06/28/2001 | CA2395435A1 Cosmid dna constructs and methods of making and using the same |
| 06/28/2001 | CA2395411A1 Use of dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| 06/28/2001 | CA2395300A1 Novel compounds |
| 06/28/2001 | CA2395286A1 Aspartyl proteases |
| 06/28/2001 | CA2395212A1 Polynucleotides and polypeptides encoded thereby |
| 06/28/2001 | CA2395202A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | CA2395113A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | CA2395007A1 Transporters and ion channels |
| 06/28/2001 | CA2394864A1 Novel compounds |
| 06/28/2001 | CA2394834A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2394802A1 Somnogenic activity of non-pathogenic lactic acid bacteria |
| 06/28/2001 | CA2394789A1 Proteases |
| 06/28/2001 | CA2394743A1 Inhibition of .beta.arrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia |
| 06/28/2001 | CA2394633A1 Therapeutic and/or prophylactic agent for nervous system disorder |
| 06/28/2001 | CA2394603A1 Urotensin-ii receptor antagonists |
| 06/28/2001 | CA2394049A1 Vesicle trafficking proteins |
| 06/28/2001 | CA2393855A1 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | CA2393724A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | CA2393367A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2393363A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2393359A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 06/28/2001 | CA2392787A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | CA2392127A1 Tryptase inhibitors |
| 06/28/2001 | CA2392121A1 Tryptase inhibitors |
| 06/28/2001 | CA2389479A1 Butyne diol derivatives |
| 06/28/2001 | CA2384326A1 Compositions and methods for l-nucleosides, l-nucleotides, and their analogs |
| 06/28/2001 | CA2363837A1 Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 06/27/2001 | EP1110957A1 Benzazole derivatives and their use as JNK modulators |
| 06/27/2001 | EP1110954A1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics |
| 06/27/2001 | EP1110952A1 Carboxylic acid derivates, their preparation and use |
| 06/27/2001 | EP1110544A2 Use of a film coating as taste masking coating for oral dosage forms |
| 06/27/2001 | EP1109907A1 Human cell junction pdz protein |
| 06/27/2001 | EP1109901A2 GABA B RECEPTOR SUBTYPES GABA B-R1c AND GABA B-R2 AND HETERODIMERS THEREOF |
| 06/27/2001 | EP1109896A1 Adenovirus formulations for gene therapy |
| 06/27/2001 | EP1109830A1 Mc4-r as target for the identification of compounds used to treat drug addiction |
| 06/27/2001 | EP1109821A1 49 human secreted proteins |
| 06/27/2001 | EP1109813A1 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists |
| 06/27/2001 | EP1109809A1 Pyrroloquinolines for treatment of obesity |
| 06/27/2001 | EP1109806A1 Complexes of paroxetine, with cyclodextrins or cyclodextrin derivates |
| 06/27/2001 | EP1109804A1 Chemokine receptor antagonists and methods of use therefor |
| 06/27/2001 | EP1109800A1 Novel cdk inhibitors having flavone structure |
| 06/27/2001 | EP1109799A1 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors |
| 06/27/2001 | EP1109786A1 Piperidine derivatives |
| 06/27/2001 | EP1109784A1 Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands |
| 06/27/2001 | EP1109783A2 Gaba uptake inhibitors having a pyrrolidine structure |
| 06/27/2001 | EP1109777A1 N-hydroxyacylamino compounds, process for their preparation and pharmaceutical compositions containing them |
| 06/27/2001 | EP1109579A1 Use of tgf-beta inhibitors for treating cerebral disorders |
| 06/27/2001 | EP1109573A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FACTOR XIIIa |
| 06/27/2001 | EP1109572A2 Neuroprotection |
| 06/27/2001 | EP1109565A1 Gabab1aa receptor |
| 06/27/2001 | EP1109556A2 New pharmaceutical uses for nos inhibitors |
| 06/27/2001 | EP1109554A2 Pipecolic acid derivatives for vision and memory disorders |
| 06/27/2001 | EP1109549A1 Analgesic use of podophyllotoxin for treating pain conditions in female genital organs |
| 06/27/2001 | EP1109543A1 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| 06/27/2001 | EP1109542A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
| 06/27/2001 | EP1109536A1 New solid dose form of nanoparticulate naproxen |
| 06/27/2001 | EP1109534A1 Quick release pharmaceutical compositions of drug substances |
| 06/27/2001 | EP1109533A1 Pulmonary delivery of liposome-encapsulated cannabinoids |
| 06/27/2001 | EP1109453A1 Compositions and methods for treatment of mitochondrial diseases |
| 06/27/2001 | EP0950048B1 1-phenylalkyl-1,2,3,6-tetrahydropyridines for treating alzheimer's disease |
| 06/27/2001 | EP0819113B1 Benzamides for neurodegenerative disorder treatment |
| 06/27/2001 | EP0792167B1 Monofunctional and/or polyfunctional polylysine conjugates |
| 06/27/2001 | EP0767669B1 New pharmaceutical preparation for pain management |
| 06/27/2001 | EP0660707B1 Amantadine and related compounds for use in the treatment of peripheral neuropathy |
| 06/27/2001 | CN1301298A Methods for prevention and treatment of cancer |
| 06/27/2001 | CN1301269A Template associated NPY Y2-receptor agonists |
| 06/27/2001 | CN1301265A Novel substituted arylhydroxamic acids as metalloproteinase inhibitors |
| 06/27/2001 | CN1301264A Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists |
| 06/27/2001 | CN1301255A Heterocyclically substituted amides, their production and their use |
| 06/27/2001 | CN1301173A Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment |
| 06/27/2001 | CN1301166A Steroidal saponins for treating alzheimer's disease |
| 06/27/2001 | CN1301164A New treatment for nervous disorders |
| 06/27/2001 | CN1301161A Serotonergic 5HT receptor compounds for treating ocular and CNS disorders |
| 06/27/2001 | CN1301159A Cabergoline and pramipexole: new uses and combinations |